secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001193125-25-044406
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian Therapeutics enters $300M ATM equity offering with Jefferies; terminates prior $175M ATM
--------------------------------------------------------------------------------

- New Open Market Sale Agreement with Jefferies LLC allows sale of up to $300M in common stock.
- Proceeds to fund clinical development of veligrotug and other candidates, plus commercialization preparation.
- Prior $175M ATM agreement terminated; $115.2M of shares sold under it.
- Jefferies will receive up to 3% commission on gross proceeds; no obligation to sell shares.
- Company may suspend or terminate sales at any time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312525044406/0001193125-25-044406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312525044406/d909216d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-044406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer